Lindahl was the legal advisor to PledPharma AB (publ) in connection with the company’s listing change from Nasdaq First North to Nasdaq Stockholm’s main market. Trading on Nasdaq Stockholm began on 31 October 2019.
PledPharma is a pharmaceutical drug development company that focuses on improving the treatment of serious medical conditions with a significant medical need. The company has two drug candidates in clinical development. PledOx® is a first-in-class drug candidate designed to prevent nerve damage associated with chemotherapy. A global Phase III programme is ongoing. Aladote® is a first-in-class drug candidate that is being developed to reduce acute liver damage caused by paracetamol poisoning. A proof-of-principle study, Phase Ib/IIa, has been successfully completed and the design of the next study is being completed. PledPharma’s head office is in Stockholm.
Lindahl’s team consisted of Gunnar Mattsson, Erika Svensson, Disa Almqvist, Helena Lindbäck and Therese Norenäs. A number of other employees also contributed to various parts of the project.
